Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | NPY4R | P50391 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.44 |
| ▸ | BACE1 | P56817 | 6/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774660 | 1.00 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30662327 | 1.00 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30785146 | 1.00 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30807971 | 1.00 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL31484226 | 1.00 | FOLH1 (0.58) | FOLH1ERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30193392 | 0.98 | FOLH1 (0.60) | FOLH1ERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL29679880 | 0.96 | FOLH1 (0.53) | FOLH1ERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL30959072 | 0.96 | FOLH1 (0.53) | FOLH1ERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL31097674 | 0.95 | FOLH1 (0.55) | FOLH1ERAP2ERAP1LNPEPNPY1R | |
| SCHEMBL31097668 | 0.95 | FOLH1 (0.55) | FOLH1ERAP2ERAP1LNPEPNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777875-B1 | SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS | 3 D MATRIX LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-3548105-B1 | METHOD FOR PRODUCING A PEPTIDE-BASED NANO FIBER STRUCTURE AND A NANO FIBER STRUCTURE THUS OBTAINED | HUMANA MEDICAL S R L (IT) | 2025-03-05 | — | — | EP | disclosed |
| US-12006085-B2 | Fill-finish process for peptide solutions | 3-D MATRIX, LTD. (JP) | 2024-06-11 | — | — | US | disclosed |
| US-11839694-B2 | Compositions and methods for promoting hemostasis and other physiological activities | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230190864-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3-D MATRIX, LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-2283851-B1 | Compositions for promoting hemostasis | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220324601-A1 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-10-13 | — | — | US | disclosed |
| EP-4049671-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220258900-A9 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| EP-4023240-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190864-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | IAPP, NGLY1, VIP | FOLH1 761/4885ERAP2 894/4885ERAP1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.